Daniel Kaye - CME Independent Director
| CHME34 Stock | BRL 331.99 6.48 1.99% |
Insider
Daniel Kaye is Independent Director of CME Group since 2019.
| Age | 64 |
| Tenure | 5 years |
| Phone | 312 930 1000 |
| Web | https://www.cmegroup.com |
Daniel Kaye Latest Insider Activity
Tracking and analyzing the buying and selling activities of Daniel Kaye against CME stock is an integral part of due diligence when investing in CME. Daniel Kaye insider activity provides valuable insight into whether CME is net buyers or sellers over its current business cycle. Note, CME insiders must abide by specific rules, including filing SEC forms every time they buy or sell CME'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Daniel Kaye over three weeks ago Acquisition by Daniel Kaye of 4306 shares of Axa Equitable subject to Rule 16b-3 |
CME Management Efficiency
The company has return on total asset (ROA) of 0.0102 % which means that it generated a profit of $0.0102 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0992 %, meaning that it generated $0.0992 on every $100 dollars invested by stockholders. CME's management efficiency ratios could be used to measure how well CME manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Dermot OBrien | Automatic Data Processing | 53 | |
| Li Ho | Taiwan Semiconductor Manufactur | N/A | |
| Brian Michaud | Automatic Data Processing | 51 | |
| John Thelan | Costco Wholesale | N/A | |
| Michael Bonarti | Automatic Data Processing | 58 | |
| Sanjay Mehrotra | Micron Technology | 64 | |
| Brock Albinson | Automatic Data Processing | 48 | |
| Ozlem MD | BIONTECH SE DRN | 56 | |
| Manish Bhatia | Micron Technology | 51 | |
| Timothy Arthurs | Extra Space Storage | 64 | |
| Sumit Sadana | Micron Technology | 54 | |
| Don McGuire | Automatic Data Processing | 63 | |
| Ryan Richardson | BIONTECH SE DRN | 44 | |
| Richard II | Taiwan Semiconductor Manufactur | N/A | |
| Vipul Nagrath | Automatic Data Processing | N/A | |
| Scott Powers | Automatic Data Processing | 60 | |
| Rob Beard | Micron Technology | N/A | |
| HorngDar Lin | Taiwan Semiconductor Manufactur | N/A | |
| Maria Black | Automatic Data Processing | 49 | |
| Russell Miller | Costco Wholesale | 66 | |
| Grace Kunde | Extra Space Storage | 48 | |
Management Performance
| Return On Equity | 0.0992 | |||
| Return On Asset | 0.0102 |
CME Group Leadership Team
Elected by the shareholders, the CME's board of directors comprises two types of representatives: CME inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CME. The board's role is to monitor CME's management team and ensure that shareholders' interests are well served. CME's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CME's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Charles Carey, Vice Chairman of the Board | ||
| Hilda Piell, Chief Human Resource Officer, Senior Managing Director | ||
| Ana Dutra, Independent Director | ||
| Anita Liskey, Sr Communications | ||
| Daniel Glickman, Lead Independent Director | ||
| Deborah Lucas, Independent Director | ||
| Jack Tobin, Chief Accounting Officer | ||
| Larry Gerdes, Independent Director | ||
| Kathleen Cronin, Senior Managing Director, General Counsel, Corporate Secretary | ||
| Howard Siegel, Independent Director | ||
| Dennis Chookaszian, Independent Director | ||
| Kendal Vroman, Senior Managing Director - International and Optimization Services | ||
| Phyllis Lockett, Independent Director | ||
| Terry Savage, Independent Director | ||
| Jonathan Marcus, Sr Counsel | ||
| Derek Sammann, Senior Managing Director - Commodity and Options | ||
| Gedon Hertshten, Independent Director | ||
| Kevin Kometer, Chief Information Officer, Senior Managing Director | ||
| Julie Winkler, Senior Managing Director, Chief Commercial Officer | ||
| Elizabeth Cook, Independent Director | ||
| Ronald Pankau, Independent Director | ||
| Daniel Kaye, Independent Director | ||
| Yra Harris, Independent Director | ||
| Terrence Duffy, Executive Chairman of the Board, Chief Executive Officer | ||
| John Pietrowhicz, Chief Financial Officer | ||
| Michael Spencer, Director | ||
| John Peschier, Managing Relations | ||
| Martin Gepsman, Independent Director | ||
| Sunil Cutinho, President - CME Clearing | ||
| Julie Holzrichter, Chief Operating Officer, Senior Managing Director | ||
| William Hobert, Independent Director | ||
| Sean Tully, Senior Managing Director - Financial and OTC Products | ||
| Timothy Bitsberger, Independent Director | ||
| Patrick Maloney, Independent Director | ||
| Eileen Keeve, Managing Devel | ||
| William Shepard, Independent Director | ||
| Dennis Suskind, Independent Director |
CME Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CME a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0992 | |||
| Return On Asset | 0.0102 | |||
| Profit Margin | 0.54 % | |||
| Operating Margin | 0.60 % | |||
| Current Valuation | 341.49 B | |||
| Shares Outstanding | 1.44 B | |||
| Price To Earning | 10.55 X | |||
| Price To Book | 2.27 X | |||
| Price To Sales | 69.07 X | |||
| Revenue | 5.02 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in CME Stock
When determining whether CME Group is a strong investment it is important to analyze CME's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CME's future performance. For an informed investment choice regarding CME Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CME Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.